This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
CUA 2018
CUA 2018 Bladder Cancer
CUA 2018
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Stone Disease
Minimally Invasive Procedures
Lower Urinary Tract Symptoms
Leadership, Communication and Practice Management
CUA 2018 Bladder Cancer
Viewing 101-120 of 10957 articles
ASCO GU 2024: Longitudinal Tumor-Informed ctDNA Assay and Patient Outcomes in Testicular Cancer
ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for First-Line Treatment of Advanced RCC: Long-Term Follow-up Data from the Phase 3 CheckMate 214 Trial
ASCO GU 2024: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced RCC: Results from 55-Month Follow-up of the CheckMate 9ER Trial
ASCO GU 2024: Evaluating Prognostic Models for Stage I Seminoma Within the Randomised Trial of Imaging and Surveillance in Seminoma Testis (TRISST)
ASCO GU 2024: Cabozantinib plus Atezolizumab in Locally Advanced/metastatic Adrenocortical Carcinoma: Results from a Multi-Cohort Basket Phase II Trial, CABATEN/GETNE-T1914
ASCO GU 2024: Survivorship Issues Beyond 2 Years After Treatment in Testicular Germ Cell Tumors: Experience from a Large Center in the United Kingdom
ASCO GU 2024: The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors
ASCO GU 2024: First-line Pembrolizumab plus Lenvatinib for Non–clear Cell RCC: Extended Follow-up of the Phase 2 KEYNOTE-B61 Study
ASCO GU 2024: The Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era of Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis of 2319 Patients
ASCO GU 2024: Evaluating Intermediate Endpoints for Overall Survival in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: An IMDC Study
ASCO GU 2024: Discussant: Adjuvant Treatment for RCC – Strategies on How to Optimize Patient Selection for The New Standard of Care
ASCO GU 2024: AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma Versus Observation (Late-Breaking Abstract)
ASCO GU 2024: Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression
ASCO GU 2024: Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results from Part B of the Randomized, Phase 3 CheckMate 914 Trial
ASCO GU 2024: Overall Survival Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell RCC
ASCO GU 2024: Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma (PemCab)
ASCO GU 2024: Avelumab First-Line Maintenance Therapy for Locally Advanced/metastatic Urothelial Carcinoma: Results from the Real-World US PATRIOT-II Study
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
ASCO GU 2024: GDFather-Neo - Neutralizing GDF-15 in MIBC: A Neoadjuvant Immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab
ASCO GU 2024: Enfortumab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma: Subgroup Analyses Results from EV-302, a Phase 3 Global Study
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free